SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. on June 25, 2021. The registrant is a Nevada corporation with principal executive offices in Boston, MA, and its common stock trades on the Nasdaq Capital Market under the symbol "PIRS". The report serves to disclose material information under Regulation FD.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure notice rather than a financial statement report.
Material Changes
No material financial changes or comparative period data are detailed within the body of this filing. The report focuses on the dissemination of a press release and an investor presentation.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure: The company issued a press release on June 25, 2021, furnished as Exhibit 99.1.
- Investor Presentation: A June 2021 Investor Presentation is attached as Exhibit 99.2.
- Incorporation by Reference: The information in Item 7.01 and its exhibits is explicitly not deemed "filed" for purposes of the Securities Act or the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release) for the specific material event or announcement triggering this filing.
- Review Exhibit 99.2 (Investor Presentation) for updated business outlook, pipeline data, or financial guidance not included in the 8-K text.
- Verify that the press release and presentation are available on the company's investor relations website or EDGAR database, as they are not embedded in the filing text.